Fraunhofer Venture has unveiled an accelerator for businesses based on its research in areas including artificial intelligence, digital medicine and industry 4.0.

Taikang and WuXi-backed CStone Pharmaceuticals has priced its shares near the middle of its proposed range to raise $285m in proceeds at a valuation of $1.5bn.

Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Merck Group and Johnson & Johnson both invested in a $22.6m round for the autoimmune disease drug developer, six years after it was spun off from Merck Serono.

University of Michigan will supply an initial $2.75m in funding to MemryX, Ripple Science, GreenMark Biomedical, and Give and Take, and could invest as much as $20m altogether.

Johnson & Johnson, Takeda, Chong Kun Dang and Handok were among the participants in a series B round expected to advance acne and IBD drugs into the clinic.

SetSquared-affiliated health test kit supplier Forth has procured capital from investors including Development Bank of Wales, adding to a crowdfunding campaign in 2017.

Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with 6 Dimensions Capital returning from the first tranche.

Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with all investors from the first tranche returning.